GlassScriptPhysician profile
Stephen David Suah
NPI 1538554951
$7,516.61
in general payments reported to CMS, 2019-2025
32 companies · $2,852 in 2025
The $2,852 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $318 · 2021: $307 · 2022: $822 · 2023: $772 · 2024: $1,654 · 2025: $2,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,074 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,073.68 |
| Education | $205.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,296.35 | 2019-2025 | Rinvoq, Botox, Skyrizi |
| Pfizer INC. | $919.77 | 2019-2025 | |
| Genzyme Corporation | $753.46 | 2022-2025 | |
| Galderma Laboratories, L.P. | $682.56 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Ucb, INC. | $545.87 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $529.44 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $362.89 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $320.85 | 2019-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $280.13 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Incyte Corporation | $254.70 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $227.72 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $191.79 | 2019-2025 | |
| Leo Pharma INC. | $144.09 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $134.98 | 2020-2024 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $129.28 | 2022-2025 | Sotyktu |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $124.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $115.81 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $96.99 | 2025 | |
| Verrica Pharmaceuticals INC. | $61.98 | 2024-2025 | Ycanth |
| Regeneron Pharmaceuticals, INC. | $47.50 | 2025 | Dupixent |
| Allergan, INC. | $44.27 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $38.39 | 2024-2025 | Fraxel, Clear+Brilliant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.94 | 2025 | Spevigo |
| Almirall LLC | $27.15 | 2024 | Klisyri |
| Dermira, INC. | $21.83 | 2020 | |
| Celgene Corporation | $21.66 | 2019 | |
| Vyne Pharmaceuticals INC. | $21.44 | 2020 | |
| Organon LLC | $20.55 | 2025 | Vtama |
| Encore Dermatology INC. | $18.57 | 2020 | |
| Dermavant Sciences, INC. | $18.29 | 2023 | Vtama |
| Journey Medical Corporation | $16.42 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Suah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.